Document is current
Any future updates will be listed below
-
Authors
Zhang, Hao
Wu, Wenjie
Wang, Meng
Zhang, Jie
Guo, Chuanbin
Han, Guojun
Wang, Lin
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2200056354 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: A single-arm, phase II trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.e18072
Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma
https://doi.org/10.1186/s12967-025-06770-2
-
Funding
Funding for this research was provided by:
Key Technologies Research and Development Program (2022YFC2406305)
the Clinical Medicine Plus X - Young Scholars Project of Peking University (PKU2022LCXQ19)
- License Information
-
More Information
Article History
Received: 12 April 2025
Accepted: 16 June 2025
First Online: 21 June 2025
Declarations
:
: The study was approved by the Ethics Committee of Peking University School and Hospital of Stomatology (No. PKUSSIRB-202170179 and No. PKUSSIRB-202276072). And written informed consent was obtained from all participants.
: All the authors approved the publication.
: The authors declare that they have no competing interests.
